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Irritant Activation of Epithelial Cells Is Mediated via
Protease-Dependent EGFR Activation
Kellie J. White1,2, Vincent J. Maffei1, Marvin Newton-West1,2 and Robert A. Swerlick1,2
Although numerous studies have examined in vivo and in vitro effects of irritants, most focused on events
developing hours to days after exposure. Molecular events occurring immediately after skin contact remain
incompletely defined. Characterization of early events could lead to the identification of key molecular signals
necessary for the production of inflammatory mediators responsible for the signs and symptoms of irritant
contact dermatitis (ICD). HaCaT cells treated with sodium lauryl sulfate (SLS), a model irritant, were used to
examine early molecular events of ICD. Western analysis showed SLS-mediated induction of early growth
response-1 (egr-1), a transcription factor capable of regulating hallmarks of ICD such as angiogenesis,
hyperproliferation, and inflammation. Additionally, de novo egr-1 expression was commensurate with
transcriptional activation of egr-1 mRNA and heteronuclear RNA. Use of pharmacological inhibitors
demonstrated that SLS-induced egr-1 was dependent on MEK1/p44/42 ERK, but not on p38 or JNK signaling.
The EGFR inhibitor PD168393 and the metalloprotease inhibitor TAPI-2 both inhibited SLS-induced egr-1. Finally,
small interfering RNA silencing of the EGFR diminished SLS-induced egr-1 mRNA. These studies suggest a role
of the EGFR in SLS signaling as well as a, to our knowledge, previously unreported association between ICD and
EGFR induction of egr-1.
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INTRODUCTION
Irritant contact dermatitis (ICD), a pathological condition
induced by exposure of skin to irritant compounds, is
characterized clinically by inflammation and, in severe
cases, ulcerations (Nethercott, 1996). ICD is particularly
prevalent in occupational settings; in industrialized countries,
occupational dermatitis may account for B30% of work-
related illness (English, 2004). Thus, identifying components
involved in irritant signaling holds therapeutic potential for
treating and preventing ICD while decreasing incidences
of occupational dermatitis.
The number of known irritants is expansive and includes
solvents, surfactants, and metals, (English, 2004), yet tradi-
tional in vitro and in vivo ICD studies utilize the model
irritant sodium lauryl sulfate (SLS) (Lee and Maibach, 1995).
These studies typically focus on molecular events occurring
hours or days after irritant exposure (Grangsjo et al., 1996;
Palacio et al., 1997; Newby et al., 2000; Moon et al., 2001;
Loffler and Happle, 2003; Torma et al., 2006; de Jongh et al.,
2006b). Consequently, early irritant-induced responses are
incompletely defined.
In this study, we utilized cultured primary human
keratinocytes (PHKs) and immortalized HaCaT cells to
investigate a role of SLS mediation of ICD signaling events.
Our initial studies demonstrated upregulation of early growth
response gene 1 (egr-1) protein with concomitant increased
egr-1 transcription in SLS-treated HaCaT cells. This in vitro
HaCaT model served to define a, to our knowledge,
previously unreported molecular mechanism by which
irritants, such as SLS, may trigger inflammatory reactions.
We hypothesized that irritants induce analogous signaling
cascades as those in wound repair, and thus focused
on signaling mechanisms involved in epidermal wounding.
Our data strongly support a role of p44/42 ERK activation in
SLS-mediated induction of egr-1 in part via protease-
dependent engagement of the EGFR. These data provide the
first evidence that pro-inflammatory factors such as IL-8, egr-
1, and vascular endothelial growth factor (VEGF) are induced
via protease-dependent EGFR activation in response to
irritant exposure in epithelial cells.
RESULTS
SLS induces egr-1 in HaCaT and PHK cells
Multiple studies have identified the induction of a variety
of pro-inflammatory cytokines associated with irritant
skin injury, evident hours to days after irritant exposure.
Our goal was to characterize early signaling events that
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occur following cellular stimulation with the model
irritant SLS.
Detergents, the most common irritants responsible for ICD
(Dickel et al., 2002), are frequently used as standards for
in vivo models of human ICD (Lee and Maibach, 2006).
Before identifying activation pathways relevant to irritant
molecular signaling, treatment conditions were established.
We examined a range of concentrations (0.001–0.008% v/v)
and exposure times (30 minutes to 4 hours) to SLS and
determined that 485% of HaCaT cells were viable after
4 hours of exposure to 0.004% SLS using the trypan blue
exclusion assay (data not shown).
We postulated that treatment of cultured cells with irritants
such as SLS would initiate pro-inflammatory cascades via
activation and/or de novo synthesis of relevant transcription
factors. Many instances of inflammation exhibit activation of
NF-kB p50/p65 proteins; thus, this transcription factor was
examined first only to find that no evidence of NF-kB DNA
binding, let alone nuclear translocation, was present follow-
ing SLS treatment (data not shown).
Given its responsiveness to injurious stimuli and wound
healing (Thiel and Cibelli, 2002), we identified egr-1 as a
transcription factor of interest. Induction of nuclear egr-1
protein was both dose- and time-dependent (Figure 1a and
Supplementary Figure S1a online, respectively) following SLS
treatment in HaCaT cells. Maximal egr-1 protein expression
was induced by 0.004% SLS (Figure 1a); moreover, in PHK
0.004% SLS induced a time-dependent increase in egr-1
(Supplementary Figure S1b online). Therefore, in combina-
tion with permissible cell viability, 0.004% SLS was selected
as a standard for subsequent studies.
Egr-1 mRNA production also showed a similar time-
dependency peaking after 1 hour of SLS treatment and
diminishing by 4 hours (Figure 1b). Real-time PCR cDNA
primers spanning an intron–exon interface measured hetero-
nuclear RNA (hnRNA) before splicing into mRNA, which
was used to distinguish increased transcriptional activity
from increased mRNA stability (Elferink and Reiners, 1996;
O’Reilly et al., 2003). SLS increased egr-1 hnRNA in a time-
dependent manner as maximal induction occurred one-half
hour after treatment and decreased by 2 hours (Supplemen-
tary Figure S1c online). In addition, pretreatment of HaCaT
cells with cycloheximide before SLS failed to inhibit egr-1
mRNA production, suggesting that new protein synthesis was
unnecessary for egr-1 gene transcription (data not shown).
Therefore, SLS appears to rapidly increase egr-1 gene
transcription as well as de novo egr-1 protein synthesis.
The role of MAP kinases in SLS-induced egr-1 production
Treatment of HaCaT cells with SLS activates signaling
pathways that result in gene activation and new protein
synthesis. However, the signaling cascade responsible for
SLS-induced egr-1 in keratinocytes remained to be defined.
p38 and JNK are both induced by stress and cytokines,
whereas p44/42 ERK is activated by growth factors and the
skin irritant phorbol 12-myristate 13-acetate (Dong et al.,
2002). Additional studies link activation of MAP kinases
to egr-1 biosynthesis (Thiel and Cibelli, 2002); therefore, we
employed specific pharmacological MAP kinase inhibitors to
probe for MAP kinase-driven egr-1 production. SLS induction
of egr-1 protein (Figure 2a), hnRNA (Supplementary Figure S2
online), and mRNA (Figure 2b and c) were significantly
inhibited by the MEK1 inhibitor, PD98059. In contrast,
neither the JNK inhibitor SP600125 nor the p38 inhibitor
SB203580 had an effect on SLS-induced egr-1 expression
(data not shown); the same concentration of SB203580 was
effective at inhibiting tumor necrosis factor-a-induced tissue
factor (data not shown) in human dermal microvascular
endothelial cells as previously reported (O’Reilly et al.,
2003). Thus, SLS activation of MEK1/p44/42 ERK is consistent
with previous studies that demonstrate egr-1 biosynthesis
under stress conditions such as heat shock, UV radiation, and
sodium arsenite (Lim et al., 1998; Al-Sarraj and Thiel, 2004).
EGFR blockade inhibits SLS induction of egr-1
Following identification of MEK1/p44/42 ERK signaling in
SLS-induced egr-1 biosynthesis, we sought to identify the
mechanism behind SLS-induced p44/42 ERK activation.
EGFR activation might be responsible for SLS-induced egr-1
expression as many EGF-like ligands activate MAP kinases
(Yarden and Sliwkowski, 2001). Additionally, egr-1 is
induced by EGFR ligands such as transforming growth factor
alpha (TGF-a), and MEK1/p44/42 ERK signaling is closely
linked to activated EGFR. Finally, we hypothesized that the
effect of irritants on the epithelium may have comparable
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Figure 1. Sodium lauryl sulfate (SLS) induces early growth response-1
(egr-1) biosynthesis. HaCaT cells were switched to low-serum DMEM 18–24
hours before experimentation (serum starved); SLS stimulation was performed
in this medium. (a) Nuclear egr-1 levels from cells treated for 2 hours with
increasing SLS concentrations were determined via western analysis; b-actin
serves as a loading control. (b) Total RNA from cells stimulated with SLS
(0.004%) at increasing times was isolated, DNase treated, reverse transcribed,
and subjected to quantitative PCR using primers specific for human egr-1
cDNA. Transforming growth factor alpha (TGF-a) (100 ngml–1, 2 hours) acts
as a positive control. Average data from independent experiments are
expressed as fold increase of input RNA from treated samples to untreated
control ±SD. Input was normalized to 18S. Statistical significance was
determined using a paired Student’s t-test (two tailed).
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features to programs initiated by injury as EGFR activation is
crucial for promoting wound repair (Pastore et al., 2008).
Pretreatment of HaCaT cells with the specific EGFR
inhibitor PD168393 completely ablated SLS-induced egr-1
protein (Figure 3a), hnRNA (Supplementary Figure S3a and c
online), and mRNA (Supplementary Figure S3b and d online);
TGF-a-induced egr-1 protein, hnRNA, and mRNA were
significantly impaired (data not shown, Supplementary Figure
S3 online). These data were supported by inhibition of SLS-
induced egr-1 biosynthesis by an additional and distinct
EGFR inhibitor AG1478 (data not shown). PD168393 also
significantly inhibited egr-1 mRNA in PHK, although due to
high basal levels of egr-1 mRNA, fold induction by SLS
was considerably lower than HaCaT cells (Supplementary
Figure S4 online). Finally, PD168393 disrupted MEK1/p44/42
ERK signaling in HaCaT cells as determined by inhibition of
phospho-p44/42 ERK (Figure 3a). Furthermore, the platelet-
derived growth factor receptor inhibitor AG1295 failed to
inhibit SLS-induced egr-1 biosynthesis or p44/42 ERK
activation supporting specificity for signaling through EGFR
(Figure 3; Supplementary Figure S3a online).
The pharmacological inhibitor data strongly support a role
of EGFR as an upstream regulator of egr-1 induction
following SLS stimulation. To strengthen this claim, small
interfering RNA (siRNA) was used to selectively knockdown
EGFR expression. No reduction in EGFR mRNA occurred in
nonsense siRNA-treated cells (Supplementary Figure S5a
online). Compared with both no siRNA and nonsense siRNA
controls, EGFR mRNA was reduced 85–90% in EGFR siRNA-
treated cells (Supplementary Figure S5a and b online,
respectively). As expected, TGF-a-induced egr-1 mRNA was
reduced in EGFR siRNA-treated cells compared with the no
siRNA control and nonsense siRNA cells (Supplementary
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Figure 2. The MAP kinases MEK1/p44/42 ERK are required for early growth response-1 (egr-1) biosynthesis following sodium lauryl sulfate (SLS) stimulation.
Serum-starved HaCaT cells were pretreated for 30 minutes with 25 mM PD98059 or DMSO vehicle control before adding transforming growth factor alpha
(TGF-a) (100 ngml–1, 2 hours) or 0.004% SLS as indicated. (a) Nuclear protein was isolated 2 hours post-treatment and subjected to western analysis to
determine the impact of PD98059 on SLS-induced egr-1; b-actin serves as a loading control. (b) Quantitative PCR was performed with primers for human cDNA
to determine changes to egr-1 mRNA. Representative results are expressed as fold increase of input RNA in treated samples over untreated control ±SD.
Input was normalized using 18S. (c) Average inhibition of egr-1 mRNA by PD98059 ±SD; statistical significance was determined using a paired Student’s
t-test (two tailed).
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Figure 3. Inhibition of the EGFR inhibits sodium lauryl sulfate (SLS)-
mediated p44/42 ERK activation and induction of early growth response-1
(egr-1); SLS induces EGFR activation. (a) Nuclear proteins from serum-starved
HaCaT cells pretreated for 30 minutes with 62.5 nM of the EGFR inhibitor
PD168393 or the platelet-derived growth factor receptor inhibitor AG1295
before addition of SLS (0.004%, 2 hours) were subjected to western analysis
using anti-egr-1 and anti-phospho-p44/42 ERK antibodies; p44/42 ERK acts as
a loading control. (b) Cytoplasmic proteins from serum-starved HaCaT cells
pretreated 1 hour with chloroquine (100mM) before SLS (0.004%, 2 hours)
or transforming growth factor alpha (TGF-a) (5 ngml–1, 2 hours) were
subjected to western analysis. The blots were probed with anti-phospho-
Y1173 EGFR and anti-EGFR. Data represent at least three independent
experiments.
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Figure S5c and d online). Furthermore, treatment with
specific EGFR siRNA prevented egr-1 mRNA induction that
was significant over nonsense siRNA, eliminating any
nonspecific effects (Supplementary Figure S5c and d online).
SLS induces EGFR activation
As a receptor tyrosine kinase, EGFR becomes autopho-
sphorylated following activation. We examined SLS-induced
EGFR activation by determining the presence of phospho-
Y1173, a major autophosphorylation site, via western
analysis. Cytoplasmic fractions from both HaCaT cells
and primary keratinocytes were resolved by SDS-PAGE and
probed with anti-phospho-Y1173 EGFR. Interestingly, SLS
induced a time- and dose-dependent increase in phospho-
Y1173 EGFR in PHK (Supplementary Figure S6 online,
data not shown), but no phosphorylation was evident in
HaCaT cells aside from the TGF-a control (data not shown).
Despite the ability of EGFR siRNA and pharmacological
inhibitors to inhibit SLS-induced egr-1, phospho-Y1173 EGFR
in HaCaT cells could not be readily detected. The rate
of EGFR internalization and degradation can vary depending
on the stimulating ligand and cell type (Wiley, 2003).
Chloroquine has been previously reported to prevent inter-
nalization and degradation of the IFN-g receptor INFgR1
through an unknown mechanism (Gira et al., 2009). HaCaT
cells were pretreated with chloroquine before SLS to allow
visualization of activated EGFR. Whereas no phospho-Y1173
EGFR was evident in HaCaT cells treated with SLS alone,
cells treated with chloroquine before SLS exhibited robust
phospho-Y1173 EGFR (Figure 3b); this phosphorylation
was not evident until at least 30 minutes of SLS treatment
(data not shown), despite activation of p44/42 ERK as soon as
5 minutes after SLS treatment (data not shown). These data
confirm that SLS induced EGFR activation in both cell types.
Metalloprotease activity mediates transactivation of EGFR
following SLS stimulation
EGFR may become activated via an extracellular, ligand-
dependent pathway following either the addition of exogen-
ous ligand, e.g., TGF-a, or release of membrane-bound EGFR
ligand(s). This latter mechanism can occur in a variety of
contexts via activation of membrane-associated metallopro-
teases (Sanderson et al., 2006). The data above support a role
of EGFR in SLS-induced egr-1 production suggesting the
involvement of the EGFR/TGF-a activation pathway in early
events in ICD. However, the mode of SLS activation of EGFR
required further study.
Many of the ligands that activate the EGFR require
protease cleavage to become biologically active (Blobel,
2005). SLS could activate an EGFR ligand-cleaving metallo-
protease resulting in EGFR transactivation. To determine
whether SLS signaling requires ectodomain shedding, HaCaT
cells were pretreated with the metalloprotease inhibitor,
TAPI-2, before SLS. TAPI-2 inhibited SLS-induced egr-1
protein (Figure 4a), hnRNA (Supplementary Figure S7 online),
and mRNA (Figure 4b and c); moreover, TAPI-2 had no effect
on TGF-a-induced egr-1 (Figure 4 and Supplementary Figure
S7 online). These data support the hypothesis that irritants
such as SLS induce cell activation and inflammation via a
protease-dependent EGFR pathway. Future studies will focus
on identifying the specific metalloproteases and EGFR ligands
responsible.
Untreated
TGF-α 0.004% SLS
Egr-1
β-Actin
TAPl-2+ +
0.004% SLS
TAPI-2
TGF-α 1 hour0.5 hours
P=0.009
n=6
0.004% SLS
P=0.7
%
 T
AP
I-2
 in
hi
bi
tio
n
o
f e
gr
-1
 m
RN
A
60
40
20
0
80
100 n=3
P<0.0001
n=6
TGF-α 1 hour0.5 hours
15
0
10
5Eg
r-1
 m
RN
A
(fo
ld 
ov
er 
un
tre
ate
d c
on
tro
l) No inhibitor
Figure 4. Sodium lauryl sulfate (SLS)-induced early growth response-1 (egr-1) expression is sensitive to the metalloprotease inhibitor TAPI-2. Serum-starved
HaCaT cells were pretreated for 30 minutes with TAPI-2 (25 mM) before stimulation. (a) Changes to nuclear egr-1 protein at 2 hours after SLS or transforming
growth factor alpha (TGF-a) (5 ngml–1) treatment were ascertained via western analysis (b) RNA was isolated and processed as described in Materials and
Methods. Inhibition of SLS-induced egr-1 mRNA was determined using real-time PCR primers specific for human egr-1 cDNA. TGF-a (25 ngml–1, 2 hours) acts
as a negative control for protease effect. Representative data are expressed as fold increase of input RNA from treated samples over untreated control ±SD.
Input was normalized using 18S. (c) Average inhibition of egr-1 mRNA by TAPI-2 ±SD; statistical significance was determined using a paired Student’s t-test
(two tailed).
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SLS induces IL-8 and VEGF mRNAs through activation of EGFR
Following identification of components involved in SLS
signaling upstream of egr-1, we looked for additional relevant
protease-sensitive, EGFR-dependent SLS-inducible genes. SLS
and other irritants have previously been shown to induce
VEGF and IL-8 in keratinocytes both in vivo and in vitro
(Wilmer et al., 1994; Grangsjo et al., 1996; Torma et al.,
2006; de Jongh et al., 2006b). These studies varied
significantly in SLS concentration; moreover, 4 hours post-
treatment was the earliest time point examined (Torma et al.,
2006), and no mechanisms for VEGF induction were
proposed. We hypothesized that SLS treatment induces these
pro-inflammatory agents via release of EGF-like ligands and
engagement of EGFR.
As previously demonstrated, SLS treatment of HaCaT cells
showed a time-dependent increase in both IL-8 and VEGF
mRNAs (data not shown). Consistent with our hypothesis, the
upregulation of these pro-inflammatory mRNAs was inhibited
by the MEK inhibitor PD98059 (data not shown), the protease
inhibitor TAPI-2 (Supplementary Figure S8 online), and the
EGFR inhibitors AG1478 and PD168393 (Figure 5), but not
AG1295 (Figure 5). Furthermore, PD168393, but not
AG1295 also significantly inhibited SLS-induced IL-8 mRNA
in PHK (Supplementary Figure S9 online); induction of VEGF
was minimal due to high baseline levels of VEGF mRNA
(data not shown). These data support that SLS induction of
VEGF and IL-8 mRNAs appears to depend on both EGFR and
metalloproteases.
SLS induces egr-1 and IL-8 in in vivo tissue
As metabolically active epidermal cells are ultimately
responsible for irritant response and inflammatory mediator
production, SLS exposure in our in vitro model may not
be predictive of the mediators induced in vivo. In order to
examine whether in vivo SLS treatment of skin resulted in
induction of the same genes observed in vitro, we measured
egr-1, IL-8, and VEGF mRNAs in normal human skin treated
for 6 hours with 20% SLS. Treatment of intact skin with SLS
induced statistically significant upregulation of egr-1 mRNA
(Supplementary Table S1 online). In addition, SLS treatment
caused variable induction of IL-8 mRNA (Supplementary
Table S1 online), but no consistent increase of VEGF mRNA
(Supplementary Table S1 online). These data demonstrate
a similar pattern of gene activation induced in vivo as what
we observed in vitro.
DISCUSSION
Irritant injury is one of the most common skin afflictions, yet
has been subjected to only modest basic research. Searching
the Medline database (1950-present) using the term irritant
dermatitis yields slightly more than 3000 references, most of
which focus on clinical aspects of this condition. Studies
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Figure 5. EGFR inhibitors diminish sodium lauryl sulfate (SLS)-induced IL-8 and vascular endothelial growth factor (VEGF) mRNAs. Serum-starved HaCaT
cells were pretreated for 30 minutes with 62.5 nM AG1478, PD168393, or AG1295 before adding 0.004% SLS or transforming growth factor alpha (TGF-a)
(5 ngml–1) for an additional hour. Total RNA was isolated and processed as described in Materials and Methods. Primers specific for human (a) IL-8 and (b) VEGF
cDNAs were utilized in real-time PCR for quantification of mRNA induced by SLS treatment. Representative results are expressed as fold increase in input RNA
in treated samples over untreated control cells ±SD. Input was normalized using 18S. Data were combined to determine average inhibition of (c) IL-8 and
(d) VEGF mRNAs ±SD; statistical significance was determined using a paired Student’s t-test (two tailed).
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examining the mechanisms involved in the elicitation of ICD
have demonstrated the expression of a host of pro-inflam-
matory cytokines, which is not surprising given the nature of
the disorder. The mechanisms linking the exposure of skin
to the irritant and the resulting gene activations remain
incompletely defined.
At the most basic level induction of pro-inflammatory
genes generally requires induction and/or activation of
transcription factors. We initially focused on such factors as
targets for irritant effects and found that SLS rapidly induces
the expression of the transcription factor egr-1. Previous
studies linking egr-1 induction to EGFR activation encour-
aged us to explore the role of EGFR in this induction. Our
studies demonstrated unambiguous protease-dependent acti-
vation of EGFR and resultant production of egr-1 mRNA and
protein as well as IL-8 and VEGF mRNAs in vitro.
This irritant-mediated protease-dependent mechanism
of EGFR activation shares distinct similarities with what has
previously been described in wound healing models (Pastore
et al., 2008). Physical injury to keratinocytes results in
protease-dependent release of EGFR ligands. Thus, irritant
effects appear to function within the continuum of mechan-
isms previously described for focal epithelial injury. This is
not entirely surprising, and perhaps irritant effects should be
classified as field injury in contrast to focal injury.
Despite the findings in this study, additional questions
remain. Previous studies examining targets for irritant injury
suggested that irritant-mediated disruption of barrier function,
via effects on the stratum corneum (SC), is the exclusive target
and mechanism for irritant-induced inflammation; these
conclusions relied on models that used either tape stripping
or acetone treatment of human or mouse skin (Wood et al.,
1992, 1996; Rissmann et al., 2009). However, the data
generated in these models discount the possibility of direct
effects of irritants on skin cells including keratinocytes
in vivo. Studies of SLS penetration into human and rodent
skin clearly demonstrate penetration of SLS into the epidermis
at concentrations consistent with those used in our in vitro
studies (Fullerton et al., 1994; Patil et al., 1995; de Jongh
et al., 2006a). Furthermore, studies that purport exclusive SC
targeting used models that neglect potential mediation of
effects via non-SC targets. Tape stripping is not a standardized
technique, and the mechanical stretching involved may have
effects on skin components other than the SC. Additionally,
acetone likely penetrates deeper than the SC, and previous
studies fail to address this effect. Whether or not irritants
such as SLS can activate signaling pathways independent of
SC perturbation in vivo is still an open question. When we
compared genes activated by SLS in a simplified system
in vitro and compared them with genes activated in vivo, we
were able to identify almost 50 genes that were upregulated
in both models (Supplementary Table S2 online). The
overlapping pattern of gene activation between HaCaT cells
in vitro and patch tests in vivo suggests strongly that
inflammatory gene activation in vivo after SLS exposure
may not be exclusively dependent upon SC perturbation.
Although our data demonstrate some role of
injury-induced, protease-dependent EGFR activation, the
mechanisms mediating protease activation by irritants are
yet undefined. G-protein-linked receptor activation has been
associated with protease activation. Despite many appli-
cable keratinocyte G-protein receptors that could initiate
this cascade, Yin et al. (2007) reported that wounding of
epithelial cultures releases adenosine triphosphate, which
activates G-protein-linked purinergic receptors that subse-
quently releases EGF-like ligands by protease activity.
Additionally, adenosine triphosphate release has been linked
to irritant effects both in vitro and in vivo (Mizumoto et al.,
2002, 2003).
The role of EGFR activation in cutaneous inflammation is
still not completely defined (Pastore et al., 2008). Although
we have identified EGFR activation in keratinocytes following
SLS treatment, inhibition of EGFR for therapeutic benefits
for ICD remains controversial. Mascia et al. (2003) reported
that blocking EGFR or MEK1/p44/42 ERK with pharmacolo-
gical inhibitors increased hypersensitivity in mice , suggesting
that EGFR functions as an anti-inflammatory mediator.
Conversely, EGFR activation was suggested to be pro-
inflammatory by Cook et al. (1997) who generated mice
overexpressing amphiregulin that exhibited profound skin
inflammation and characteristics of psoriasis. The discrepan-
cies in these data suggest that the effects of EGFR activation
may be context- and cell-specific, which rely on specifics
such as the EGF-like ligand(s) released, ligand concentration,
signaling kinetics, and specific ErbB receptor subtype
activated. EGFR activation may be capable of both pro- and
anti-inflammatory roles.
Although the data presented in this manuscript focus on
EGFR signaling as an early event in response to SLS-mediated
injury, additional activation of pathways upstream of
protease activation are also relevant and require additional
study. The ability to study irritant-mediated events occurring
rapidly after irritant exposure will facilitate discovery of,
to our knowledge, previously unreported pathways relevant
to clinical observations of skin irritation.
MATERIALS AND METHODS
Reagents
SLS and AG1478 were obtained from Sigma-Aldrich (St Louis, MO).
Anti-egr-1 (C-19), anti-EGFR, and anti-phospho-Y1173 EGFR were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
phospho-p44/42 ERK, anti-GAPDH, and anti-p44/42 ERK were from
Cell Signaling Technology (Danvers, MA). The inhibitors AG1295,
PD168393, PD98059, SP600125, and SB203580 were purchased
from Calbiochem (San Diego, CA). Human recombinant TGF-a was
from PeproTech (Rocky Hill, NJ). PowerSYBR was purchased from
Applied Biosystems (Foster City, CA). All other reagents were the
best grade possible and are commercially available.
Cell culture
HaCaT cells are non-tumorigenic and form an almost normal
epidermis in vivo (Boukamp et al., 1988), suggesting that the cells
are a reasonable in vitro system for studying changes in epidermal
cells. HaCaT cells were maintained in DMEM (Mediatech, Herndon,
VA) supplemented with 10% heat-inactivated fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA) and 1 antibiotic/
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anti-mycotic solution (Mediatech) in 5% CO2 and 37 1C. Primary
keratinocytes isolated from neonatal foreskin were obtained from
Emory University Skin Diseases Research Center or Lifeline Cell
Technology (Walkersville, MD). Cells were grown in KC growth
(KGM bullet kit, Lonza, Walkersville, MD) or DermaLife K Cell
Culture Medium (Lifeline Cell Technology) and maintained at 37 1C
and 5% CO2. Before experimentation, confluent PHK (p2-6) were
starved for 24 hours in KC growth media devoid of bovine pituitary
extract and EGF.
Western blot analysis
HaCaT cells were grown as described above in 60-mm dishes. At 24
hours before treatment, the media was changed to 0.5% fetal bovine
serum DMEM or KGM without EGF. Cytoplasmic and nuclear
proteins isolated in the presence of protease and phosphatase
inhibitors were resolved using SDS-PAGE, transferred to nitrocellu-
lose membranes, and probed with anti-egr-1, anti-phospho-Y1173
EGFR, or anti-phospho-p44/42 ERK overnight at 4 1C. All antibodies
were visualized using horseradish peroxidase-conjugated secondary
antibodies (Bio-Rad, Hercules, CA). Blots were stripped using
Restore Western Blot Stripping Buffer (Pierce, Rockford, IL) per
manufacturer’s directions before reprobing with anti-EGFR or
anti-p44/42 ERK. To confirm even loading, blots were reprobed
with anti-b-actin (Stratagene, La Jolla, CA).
Real-time quantitative PCR
Before treatment, HaCaT cells were starved with 0.5% fetal bovine
serum DMEM. Cells (90–100% confluent) were treated at times and
doses indicated before total RNA was isolated using the RNeasy
Mini Kit (Qiagen, Valencia, CA) with on-column DNase I (Qiagen)
treatment to remove genomic DNA. cDNA was generated
using Superscript III Reverse Transcriptase per manufacturer’s
protocol (Invitrogen, Carlsbad, CA). Changes to gene expression
were determined using specific primers for human egr-1, EGFR,
VEGF, and IL-8 cDNAs in triplicate wells. To establish whether
the increases in egr-1 protein levels were the result of increased
transcription or translation, hnRNA reverse transcriptase-PCR
primers that overlapped an intron/exon interface on the egr-1 gene
(F-50-CTCCGTTGCGTCACTGTTG-30, R-50-ACTCCCGAGGTAGTTA
ATAATTGAC-30) were employed. Statistical significance was deter-
mined using two-tailed paired Student’s t-test; n represents the
number of independent experiments.
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